Lucid Diagnostics (LUCD) investor relations material

Executive summary

• Performed 3,177 EsoGuard tests in Q1 2026, generating $1.3 million in revenue, with test volume above target range and year-over-year growth from $0.8 million.

• Strengthened balance sheet with a $16.8–$17 million public offering, resulting in $45 million pro forma cash at quarter end, extending runway into 2027.

• Focus remains on securing Medicare coverage, with ongoing commercial and VA engagement, infrastructure buildout, and expansion of insurance reimbursement.

• Showcased EsoGuard at Digestive Disease Week, with multiple abstracts and anticipation of updated clinical guidelines highlighting EsoGuard and EsoCheck.

• First VA purchase order received and contract awarded, with robust pipeline for further expansion.

Financial highlights

• Q1 2026 revenue was $1.3 million, up from $828,000 in Q1 2025, with 72% from prior quarters' insurance claims.

• Cash at March 31, 2026, was $27.9 million; pro forma cash post-financing is $44.8–$45 million.

• Average quarterly cash burn over last four quarters was $11.3 million; Q1 burn was $12.1 million due to commercial investments.

• Non-GAAP net loss per share improved to $(0.07), about $0.03–$0.09 better than previous quarters and year-over-year.

• Operating expenses for Q1 2026 were $13.4 million, including $1.4 million in stock-based compensation.

Outlook and guidance

• Confident in near-term Medicare LCD approval, which would impact 40–50% of the addressable patient population.

• Commercial team focused on maintaining test volume and preparing for rapid Medicare-driven expansion.

• Ongoing investments in clinical evidence and real-world data generation to support payer and regulatory engagement.

• Company expects recurring losses and negative cash flow from operations to continue, with ongoing dependence on expanded reimbursement and capital raises.

• Substantial doubt exists about the ability to continue as a going concern within one year without significant revenue growth or new financing.